Latest News

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.

Scammers are stealing female urologists' headshots to run AI-driven catfishing and supplement scams; in this article, 2 urologists share their experiences with this concerning trend.

Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.

Higher saturated and animal fat intake was linked to increased mortality after nonmetastatic prostate cancer, according to a cohort study published in JAMA Network Open.

The FDA has provided an update on efforts to increase supply of estradiol transdermal patches as demand increases.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.

This episode explores evolving approaches to sexual wellness, innovation in premature ejaculation, the need for patient education, and integrating sexual health products into clinical care across the lifespan.

Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.